January 26, 2021

TMIST Sets Quarterly Accrual Record in Q4 2020

Despite the ongoing COVID-19 pandemic and the holiday season, the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) posted its three highest monthly enrollments in the fourth quarter of 2020 (Oct.–Dec.).

Since non-urgent care resumed in most parts of the United States on or around July 1, TMIST has enrolled more participants than all other National Cancer Institute trials combined. At year-end, the study had enrolled 37,893 participants at 105 sites in the United States (U.S.) and worldwide.

At a time when organized medicine is working to achieve healthcare equity, TMIST is one of the most inclusive clinical trials ever performed. Nearly 20% of the enrollees from the U.S. are Black women. The average Black cohort in U.S. clinical trials is approximately 8%.

This trial continues to recruit new sites. Email TMIST@acr.org to start a conversation about the study requirements, reimbursement/payment structure, and/or to start the application process.